MNK up +1.67% percent right now. $MNK High is at 9
Post# of 53582
Posted On: 11/10/2014 1:38:01 PM
MNK up +1.67% percent right now. $MNK High is at 92.67 and the Low 90.80 with current volume of 302,853.
Recent News posted below.
MNK Mallinckrodt Plc Ordinary Share Recent Headline News
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 92.81 (+1.75), IPXL: 28.89 (+0.32), KBIO: 1.94 (+0.14), MYL: 53.97 (+0.86)
Will Evogene (EVGN) Report Wider-than-Expected Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:10PM CST
Evogene (EVGN) is scheduled to report third-quarter 2014 results before the opening bell on Nov 10.
MNK: 92.81 (+1.75), EVGN: 10.30 (-0.20), MON: 116.24 (+1.80), DNDN: 0.23 (-0.71)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), INO: 10.87 (-0.36)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), BAX: 70.54 (-0.07), LLY: 67.93 (+1.33)
ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 92.81 (+1.75), SHPG: 200.44 (+1.86), UBS: 17.12 (+0.06)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.81 (+1.75), RNA: 11.87 (-0.27), AGIO: 79.65 (+7.59), CELG: 107.77 (+1.32)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), DNDN: 0.23 (-0.71), ICPT: 178.84 (+6.25)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 92.81 (+1.75), BDSI: 16.23 (+0.73), ISIS: 46.26 (+1.67), GSK: 45.19 (+0.28)
Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:00PM CST
Synta Pharmaceuticals Corp. (SNTA) is scheduled to report third-quarter 2014 results before the opening bell on Nov 6.
MNK: 92.81 (+1.75), SNTA: 3.12 (-0.02), INFI: 13.50 (+0.49), HSP: 56.02 (-0.30)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), PBH: 31.40 (-1.39), RPRX: 9.36 (-0.76), HSP: 56.02 (-0.30)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.81 (+1.75), VRTX: 116.45 (+0.52), BMRN: 86.94 (+3.03), GILD: 107.33 (+0.88), ALXN: 194.46 (+0.65)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), TEVA: 58.09 (+0.39)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ARIA: 6.28 (+0.20), HSP: 56.02 (-0.30)
Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), HSP: 56.02 (-0.30), KERX: 16.46 (-0.27)
Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ALNY: 99.04 (+3.20), HSP: 56.02 (-0.30)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.81 (+1.75), AGN: 195.49 (-0.51), ACT: 246.41 (+0.50), BMY: 58.60 (+0.28)
Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 92.81 (+1.75), ABT: 43.91 (+0.54), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), PFE: 30.24 (+0.32), MYL: 53.97 (+0.86)
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), RDY: 55.88 (+0.16)
Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:50AM CDT
Mallinckrodt, a firm in the Medical-Generic & Drug industry space, could again beat earnings, as it has witnessed a nice streak of crushing expectations.
MNK: 92.81 (+1.75)
Recent News posted below.
MNK Mallinckrodt Plc Ordinary Share Recent Headline News
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 92.81 (+1.75), IPXL: 28.89 (+0.32), KBIO: 1.94 (+0.14), MYL: 53.97 (+0.86)
Will Evogene (EVGN) Report Wider-than-Expected Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:10PM CST
Evogene (EVGN) is scheduled to report third-quarter 2014 results before the opening bell on Nov 10.
MNK: 92.81 (+1.75), EVGN: 10.30 (-0.20), MON: 116.24 (+1.80), DNDN: 0.23 (-0.71)
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), INO: 10.87 (-0.36)
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), BAX: 70.54 (-0.07), LLY: 67.93 (+1.33)
ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 92.81 (+1.75), SHPG: 200.44 (+1.86), UBS: 17.12 (+0.06)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.81 (+1.75), RNA: 11.87 (-0.27), AGIO: 79.65 (+7.59), CELG: 107.77 (+1.32)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), DNDN: 0.23 (-0.71), ICPT: 178.84 (+6.25)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 92.81 (+1.75), BDSI: 16.23 (+0.73), ISIS: 46.26 (+1.67), GSK: 45.19 (+0.28)
Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:00PM CST
Synta Pharmaceuticals Corp. (SNTA) is scheduled to report third-quarter 2014 results before the opening bell on Nov 6.
MNK: 92.81 (+1.75), SNTA: 3.12 (-0.02), INFI: 13.50 (+0.49), HSP: 56.02 (-0.30)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), PBH: 31.40 (-1.39), RPRX: 9.36 (-0.76), HSP: 56.02 (-0.30)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.81 (+1.75), VRTX: 116.45 (+0.52), BMRN: 86.94 (+3.03), GILD: 107.33 (+0.88), ALXN: 194.46 (+0.65)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), TEVA: 58.09 (+0.39)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ARIA: 6.28 (+0.20), HSP: 56.02 (-0.30)
Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), HSP: 56.02 (-0.30), KERX: 16.46 (-0.27)
Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ALNY: 99.04 (+3.20), HSP: 56.02 (-0.30)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.81 (+1.75), AGN: 195.49 (-0.51), ACT: 246.41 (+0.50), BMY: 58.60 (+0.28)
Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 92.81 (+1.75), ABT: 43.91 (+0.54), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), PFE: 30.24 (+0.32), MYL: 53.97 (+0.86)
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), RDY: 55.88 (+0.16)
Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:50AM CDT
Mallinckrodt, a firm in the Medical-Generic & Drug industry space, could again beat earnings, as it has witnessed a nice streak of crushing expectations.
MNK: 92.81 (+1.75)
(0)
(0)